With only one approved drug on the market, companies like Inventiva Pharma are advancing MASH drugs and seeking a competitive ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

In addition, in the coming years, oral GLP-1 receptor agonists and injectable formulations that require less-frequent ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

Unplanned pregnancies are still being reported among people using GLP-1 drugs, but now fertility specialists are ...

The following is a summary of "Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide ...

Provides longer GLP-1 receptor activation. Depending on the medication, the effects can last for a minimum of 24 hours to a ...

Metsera is riding the wave of continued enthusiasm for GLP-1 drugs and its own early-stage data to bring in a hefty $215 ...